Associated Papers
Rational design of non-resistant targeted cancer therapies.
Martínez-Jiménez F et al.
Scientific Reports, 2017
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.
Brenan L et al.
Cell Reports, 2016
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Goetz EM et al.
Cancer Research, 2014
Select a paper to view details